Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, today announced...
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for...
For the Reasons that Matter: A First‑of‑Its‑Kind Multi-Country Campaign Spotlights Adult Respiratory Health
MAKATI CITY, Philippines, April 30, 2026 /PRNewswire/ -- Pfizer Philippines, together with healthcare professionals, has launched "For the Reasons that Matter", a public awareness campaign focused on adult respiratory health. Rolling out across the...
3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a...
Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised $787 million in financing rounds. The investment included participation by a...
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation...
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology...
NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer
NEW YORK, Feb. 3, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content...
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company...